
Ali Ashkar, a professor of Pathology and Molecular Medicine specializing in immunology, is a co-author on a paper describing a new way to store fragile vaccines.
Researchers at McMaster University have invented a stable, affordable way to store fragile vaccines for weeks at a time at temperatures up to 40C, opening the way for life-saving anti-viral vaccines to reach remote and impoverished regions of the world.
The new method combines the active ingredients in existing vaccines with a sugary gel, where they remain viable for eight weeks or more, even at elevated temperatures.
The method creates light, durable, and compact doses that would be ideal for shipping Ebola vaccine, for example, to affected regions of Africa, the researchers say. The process adds only marginal cost to preparing a vaccine and eliminates almost all the cost of transporting it – which can account for 80 per cent of the total cost of inoculation.
Combining the vaccines and the sugars – pullulan and trehalose – is almost as simple as stirring cream and sugar into coffee, the researchers say. The storage technology was created by chemical engineers at McMaster, who had already demonstrated its effectiveness in other applications, such as an edible coating that can prolong the shelf life of fruits and vegetables.

To apply the technology to vaccines, the engineers collaborated with health sciences colleagues across campus who specialize in virology and immunology. Their work is published today in the journal Scientific Reports and also appeared on the front page of the Globe and Mail newspaper.
“This, to us, is the ultimate application of this technology,” said the paper’s lead author Vincent Leung, an assistant professor of Chemical Engineering. “To imagine that something we worked on in the lab could one day be used to save people’s lives is very exciting.”
The invention is significant because it can replace the cumbersome “cold chain” – constant storage at temperatures between 2C and 8C – which is currently necessary to keep anti-viral vaccines viable. Maintaining the cold chain is a significant barrier to inoculating people in remote or poor regions of the world, where the infrastructure to refrigerate and transport vaccines smoothly may not be available.
“You can spend all kinds of money developing a vaccine, but if it is deactivated by high temperature an hour before you can give it to someone, it doesn’t matter,” says co-author Ali Ashkar, a professor of Pathology and Molecular Medicine specializing in immunology.
The cold-chain challenge is so great, the researchers say, that in some regions, vaccines must be transported by camels bearing solar-powered mini-refrigerators. There are some populations that never receive vaccines.
“If you can’t get vaccines to the places where people need them, there’s no point in having them,” says co-author Matthew Miller, an assistant professor in the Department of Biochemistry and Biomedical Sciences whose laboratory specializes viral pathogens.
Not being able to get vaccines to isolated areas makes it impossible to eradicate deadly viruses. Unchecked, such viruses can devastate local populations and reach exposed pockets in more populated countries where religious, cultural or other concerns have diminished the proportion of vaccinated individuals. Such a scenario has recently been playing out in in a measles outbreak in the US northwest and Vancouver, BC.
The new vaccine-storage method suspends the active components of a vaccine in a tiny one-dose container filled with a sugar-gel combination that dries to seal in the vaccine. Later, clinicians reconstitute the vaccine with water and administer it to patients as they ordinarily would.
“Often, complex problems have simple solutions. It just takes the right team,” says Miller. “The best research comes from merging fields, when you do something with someone else that you couldn’t do alone.”
The researchers have proven the method to be viable using two sample vaccines – influenza virus and herpes simplex virus – to inoculate and test mice by exposing them to the viruses because the immune response of mice is similar to that of humans. The materials in the storage medium are already approved by the US Food and Drug Administration, simplifying the path to commercialization.
“All the pieces are ready to go,” says co-author Carlos Filipe, chair of Chemical Engineering at McMaster. “It’s actually quite simple compared to the technology required to create a vaccine itself.”
The researchers are working with a commercial partner to get the technology to market.
Learn more: McMaster researchers invent a way to get life-saving vaccines to previously inaccessible parts of the world
The Latest on: Vaccine storage
[google_news title=”” keyword=”vaccine storage” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine storage
- Hong Kong receives first batch of Covid XBB variant vaccines, prioritises the elderlyon November 30, 2023 at 11:58 am
Vaccination arrangements for the 100,000-jab batch manufactured by US drug firm Pfizer expected to be announced in December.
- Optimize Cattle Health: A Producer's Guide To Vaccine Handling And Storageon November 30, 2023 at 8:00 am
The highest quality vaccine may lose its effectiveness if not handled and stored correctly. Even experienced producers can inadvertently overlook crucial principles during the preparation and ...
- Lumen Bioscience bags $5.5 million to develop needle-free vaccineson November 30, 2023 at 5:59 am
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop ...
- Global Cold Storage Construction Industry Report 2023-2030: Offering Eco-Friendly Alternative, CO2 Refrigeration Set to Make Big Gainson November 30, 2023 at 3:14 am
The cold storage industry has witnessed significant growth, driven by the COVID-19 pandemic's impact on online grocery shopping and the need for vaccine storage. The surge in online grocery shopping ...
- New-generation XBB vaccines arriveon November 30, 2023 at 1:38 am
The first shipment of about 100,000 doses of the new-generation XBB mRNA vaccine arrived in Hong Kong, the Government says, adding that the vaccination arrangements will be announced in early December ...
- PHCC organises interprofessional education workshop on vaccine management for staffon November 29, 2023 at 2:11 pm
Tribune News NetworkDohaThe Public Health Protection Department of the Primary Health Care Corporation (PHCC) organised a workshop on Interprofessional Education for Vaccine Management from November ...
- Novavax's updated COVID-19 vaccine now option for all 194 WHO member stateson November 28, 2023 at 5:16 am
Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 ...
- First Malaria Vaccines Arrive In Cameroonon November 27, 2023 at 12:19 pm
As the clock ticked toward midnight on the night of Nov. 21 in Yaoundé, Cameroon, aid workers began unloading 331,200 doses of a new, lifesaving malaria vaccine — the world’s first — marking a major ...
- Vaccines Newson November 26, 2023 at 4:01 pm
Nov. 27, 2023 — COVID-19 caused an alarming surge in premature births, but vaccines were key to returning the early birth rate to pre-pandemic levels, according to a new analysis of California birth ...
- Regina pharmacist pleads guilty, reprimanded for administering expired COVID vaccines in 2022on November 23, 2023 at 12:43 pm
A pharmacist in Regina has been reprimanded for professional incompetence and misconduct after pleading guilty to injecting 15 patients with expired and incorrect COVID-19 vaccines a year ago, ...
via Bing News